Triamterene

General Toxicity Notes
Natriuretic drugs may cause extracellular fluid volume depletion.
Excreted Unchanged %
20
Half-Life (Normalesrd) Hours
2-12/10
Plasma Protein Binding %
55-81
Volume Of Distribution L/Kg
2.2-3.7
Dose For Normal Renal Function
25-150 mg q12-24h
Adjustment For Renal Failure Method
I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
q12h [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
Avoid [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Not applicable, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Not applicable, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Avoid
References
Fairley KF, Woo KT, Birch DF, Leaker BR, Ratnaike S. Triamterene-induced crystalluria and cylinduria: clinical and experimental studies. Clin Nephrol. 1986; 26: 169-73. [PMID: 3780069] / Seyffart G. Drug Dosage in Renal Insufficiency. Dordrecht, The Netherlands: Kluwer Academic; 1991. / Triamterene and the kidney [Editorial]. Lancet. 1986; 1: 424. [PMID: 2868346]
Toxicity Notes
Hyperkalemia common when GFR <30 mL/min, especially in diabetics. Active metabolite with long half-life in ESRD. Folic acid antagonist. Urolithiasis. Crystalluria in acid urine. May cause acute renal failure.